Avalyn Pharma (NASDAQ:AVLN) Reaches New 1-Year Low - Should You Sell?

Key Points

• Avalyn Pharma shares fell to a new 52-week low of $24.14, last trading at $24.48 versus a prior close of $25.53 and well below the 50-day moving average of $33.38.
• Analyst sentiment remains mixed but averages to a “Moderate Buy”, with a consensus price target of $60.00; ratings range from “sell” to “strong buy.”
• The clinical-stage biopharmaceutical company is developing inhaled therapies for pulmonary fibrosis, led by AP01, while analysts expect a full-year loss of approximately $3.86 per share.

Avalyn Pharma Inc. (NASDAQ:AVLN - Get Free Report)'s stock price reached a new 52-week low on Thursday. The stock traded as low as $24.14 and last traded at $24.48, with a volume of 285265 shares trading hands. The stock had previously closed at $25.53.

Analyst Ratings Changes

AVLN has been the subject of a number of research reports. Weiss Ratings assumed coverage on shares of Avalyn Pharma in a report on Thursday, August 13th. They issued a "sell (d+)" rating for the company. Raymond James Financial began coverage on shares of Avalyn Pharma in a report on Friday, October 2nd. They set an "outperform" rating and a $60.00 price objective on the stock. Wall Street Zen downgraded Avalyn Pharma from a "hold" rating to a "sell" rating in a research note on Sunday, September 20th. Finally, Morgan Stanley boosted their target price on Avalyn Pharma from $53.00 to $57.00 and gave the company an "overweight" rating in a research report on Thursday, August 13th. Two equities research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $60.00.

Avalyn Pharma Stock Performance

The firm has a market cap of $1.09 billion and a P/E ratio of -1.08. The company has a current ratio of 33.12, a quick ratio of 33.12 and a debt-to-equity ratio of 0.04. The company has a fifty day moving average price of $33.38.

Avalyn Pharma (NASDAQ:AVLN - Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.03) by $0.05. On average, equities research analysts expect that Avalyn Pharma Inc. will post -3.86 EPS for the current year.

Institutional Investors Weigh In On Avalyn Pharma

Institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of New York Mellon Corp purchased a new position in Avalyn Pharma during the 2nd quarter worth $1,321,000. State Street Corp bought a new position in shares of Avalyn Pharma during the second quarter valued at about $10,501,000. Braidwell LP purchased a new position in Avalyn Pharma during the second quarter worth about $26,382,000. Finally, Montanova Capital LLC purchased a new position in Avalyn Pharma during the second quarter worth about $82,402,000.

About Avalyn Pharma

Avalyn Pharma, Inc is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for serious fibrotic lung diseases. The company's primary focus is pulmonary fibrosis, a group of progressive conditions in which scar tissue builds up in the lungs and impairs breathing.

Avalyn's lead product candidate is AP01, an inhaled formulation of pirfenidone being developed for the treatment of idiopathic pulmonary fibrosis and other forms of pulmonary fibrosis. By delivering therapy directly to the lungs, Avalyn aims to provide a treatment option that may improve local drug exposure while potentially reducing some of the tolerability challenges associated with oral antifibrotic therapies.

The company's development programs are centered on advancing inhaled medicines through clinical testing and, if successful, regulatory review.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.